Open AccessEvolving Strategies for the Management of Hand–Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib
Author(s) -
Lacouture Mario E.,
Wu Shenhong,
Robert Caroline,
Atkins Michael B.,
Kong Heidi H.,
Guitart Joan,
Garbe Claus,
Hauschild Axel,
Puzanov Igor,
Alexandrescu Doru T.,
Anderson Roger T.,
Wood Laura,
Dutcher Janice P.
Publication year - 2008
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2008-0131
Subject(s) - sunitinib , sorafenib , medicine , oncology , hepatocellular carcinoma , quality of life (healthcare) , renal cell carcinoma , intensive care medicine , nursing
The multitargeted kinase inhibitors (MKIs) sorafenib and sunitinib have shown benefit in patients with renal cell carcinoma, hepatocellular carcinoma (sorafenib), and gastrointestinal stromal tumor (sunitinib). Their efficacy in other malignancies is currently being investigated because of their broad range of activity. The effectiveness of these drugs is somewhat diminished by the development of a variety of toxicities, most notably hand–foot skin reaction (HFSR). Although HFSR does not appear to directly affect survival, it can impact quality of life and lead to MKI dose modification or interruption, potentially limiting the antitumor effect. Currently, no standard guidelines exist for the prevention and management of MKI‐associated HFSR. To address this issue, an international, interdisciplinary panel of experts gathered in January 2008 to discuss and evaluate the best‐practice management of these reactions. Based on these proceedings, recommendations for the management of HFSR have been provided to offer patients the best possible quality of life while taking these drugs and to optimize the patient benefit associated with MKI therapy.